Literature DB >> 17542336

Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy.

D Kuang1, A Verbine, C Ronco.   

Abstract

Appropriate antimicrobial therapy poses one of the greatest challenges during the management of a septic patient in the intensive care unit (ICU). Acute renal failure (ARF) is a common complication of sepsis and often occurs as a component of multiple organ dysfunction syndrome. Continuous renal replacement therapy (CRRT) is increasingly used as an effective extracorporeal blood purification therapy in this critically ill patient population. Available data demonstrate that sepsis, ARF and different modalities of CRRT may have profound effects on the pharmacokinetics and pharmacodynamics of various antimicrobial agents used in the ICU. Guidelines for antimicrobial prescription which will fit the individual patient undergoing a particular method of treatment are still unavailable. Understanding the principles of drug removal by CRRT and pharmacokinetics of various agents can help to modify the drug dosage and dosing intervals for individualized therapy. Meanwhile, monitoring the drug serum concentration is still mandatory whenever clinically feasible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17542336     DOI: 10.5414/cnp67267

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  10 in total

1.  Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

Authors:  Sean K Gorman; Richard S Slavik; Stefanie Lam
Journal:  Can J Hosp Pharm       Date:  2012-05

Review 2.  Pharmacological issues of linezolid: an updated critical review.

Authors:  Antonello Di Paolo; Paolo Malacarne; Emanuele Guidotti; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

3.  Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Authors:  Eugenia Yeh; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

4.  Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.

Authors:  Iolanda Cirillo; Nicole Vaccaro; Dainius Balis; Rebecca Redman; Gary R Matzke
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

Review 5.  Drug Dosing in Critically Ill Patients with Acute Kidney Injury and on Renal Replacement Therapy.

Authors:  Sai Saran; Namrata S Rao; Afzal Azim
Journal:  Indian J Crit Care Med       Date:  2020-04

6.  Etanercept clearance during an in vitro model of continuous venovenous hemofiltration.

Authors:  Geoffrey M Fleming; Noha N Salama; Saada K Eid; Kenneth R Cooke; Bruce A Mueller
Journal:  Blood Purif       Date:  2009-09-01       Impact factor: 2.614

7.  Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.

Authors:  Wanda C Reygaert
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

Review 8.  Pro/con debate: continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish?

Authors:  Raymond Vanholder; Wim Van Biesen; Eric Hoste; Norbert Lameire
Journal:  Crit Care       Date:  2011-01-28       Impact factor: 9.097

9.  Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough?

Authors:  Ali S Omrani; Alaa Mously; Marylie P Cabaluna; John Kawas; Mohammed M Albarrak; Wafa A Alfahad
Journal:  Saudi Pharm J       Date:  2014-09-07       Impact factor: 4.330

10.  Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.

Authors:  Mahesh N Samtani; Nicole Vaccaro; Iolanda Cirillo; Gary R Matzke; Rebecca Redman; Partha Nandy
Journal:  ISRN Pharmacol       Date:  2012-07-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.